Children's Hospital LA pauses use of Sarepta gene therapy for all patients

Children's Hospital Los Angeles has paused the use of Sarepta Therapeutics' gene therapy, Elevidys, for all muscular dystrophy patients, citing recent FDA actions. This decision follows an FDA request for Sarepta to voluntarily halt Elevidys shipments after a patient receiving a different experimental treatment died, a request Sarepta has defied by stating it will continue providing the therapy to ambulatory patients. The hospital's move, despite Sarepta's stance and Elevidys's full FDA approval for ambulatory patients, underscores intensifying safety concerns, including prior patient deaths from liver failure, contributing to Sarepta shares falling 5% on Monday and approximately 90% year-to-date.

Analysis

Sarepta Therapeutics is facing a severe operational and reputational challenge after Children's Hospital Los Angeles, a key treatment center, paused all use of its gene therapy, Elevidys. This decision, citing recent FDA actions, significantly undermines the therapy's standing, especially as it follows a June suspension for non-ambulatory patients due to two deaths from liver failure. The situation is further intensified by Sarepta's public defiance of a voluntary FDA request to halt shipments, creating a high-stakes regulatory conflict. The hospital's pause is particularly concerning because it extends to ambulatory patients, a group for which Elevidys holds full FDA approval, indicating a critical erosion of physician confidence that transcends regulatory status. This cascade of negative events has materialized in the company's stock performance, with a 5% decline on the day of the news contributing to an approximately 90% year-to-date collapse, reflecting profound investor doubt regarding the therapy's commercial viability and future.

Key Decisions for Investors

• Investors should recognize the escalating risk profile of Sarepta, as the defiance of an FDA request and a major hospital's usage pause compound existing safety concerns and contribute to the stock's 90% year-to-date decline.
• It is critical to monitor for similar actions from the other authorized treatment centers, as a broader halt in administering Elevidys would confirm a systemic loss of clinical confidence and further impair the therapy's revenue potential.
• Given the direct regulatory conflict and unresolved safety issues, consider reducing exposure or implementing hedging strategies, as the path forward for Elevidys is highly uncertain and subject to further negative clinical or FDA developments.